- Past Issues
- e-Submission
-
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Editorial Office
- +82-01-9989-7744
- kbiolpsychiatry@gmail.com
- https://www.biolpsychiatry.or.kr/
2021 Impact Factor 1.766
5-Year Impact Factor 1.674
Korean Journal of Biological Psychiatry 2013;20(3):91-6. Published online: Mar, 1, 2013
Objectives :
The aim of this study is to evaluate the association between rs6280 and
rs905568 genetic polymorphism of DRD3 gene and the treatment response of amisulpride.
Methods : After six weeks treatment of amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression-Severity (CGI-S). The genotyping for
rs6280 and rs905568 was performed using TaqMan single nucleotide polymorphism (SNP) genotyping assay.
Results : There was no significant difference in the frequency of genotype and allele of
rs6280 between the responders and non-responders based on the total, positive, and general score of PANSS and CGI-S score. However, there was a significant association between this SNP and treatment response in the negative score of PANSS (χ2 = 5.23, p = 0.022). There was no significant association between
rs905568 and the response in positive, negative, general, and total PANSS score and CGI-S score.
Conclusions : This is the first positive association study between DRD3
gene and the treatment response of negative symptoms to amisulpride in Korean schizophrenia patients. A larger scale research on more SNP of the
DRD3
gene will make a progress in the study of pharmacogenetics on the treatment response of the amisulpride.
Keywords Treatment response;Amisulpride;<i>DRD3</i> gene;Polymorphisms;<i>rs</i>6280.